Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab in previously untreated symptomatic multiple myeloma
2022-500800-24-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of linvoseltamab and dexamethasone in multiple myeloma (MM) (2 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of treatment-emergent adverse events and 8 more. Planned start Sep 2024; status: authorised.
02
Drugs
linvoseltamabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-500800-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500800-24-00.